GleamWall
中文EN

ZIVO Zivo Bioscience, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1101026 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY164.5%
TTM net income YoY38.0%
TTM EPS YoY45.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin31.7%
Operating margin-4,045.7%
Net margin-4,059.7%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-1,608.6%
ROIC (approx.)—
Asset turnover0.40x

Leverage & solvency

Liabilities / assets687.5%
Debt / equity—
Current ratio0.08x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-1,025.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-302024Q22024-06-302024Q12024-03-312023Q4*2023-12-31
Income statement
Revenue$65,625$53,400$0$90,000$31,500$0$35,720$11,800
Cost of revenue$44,337$35,478$0$63,000$22,050$0$23,218$7,669
Gross profit$21,288$17,922$0$27,000$9,450$0$12,502$4,131
R&D expense$203,444$479,657$2.77M$243,483$326,361$2.25M$312,767$312,465
SG&A expense$836,187$1.17M$1.44M$1.38M$1.94M$5.98M$975,574$1.59M
Operating income-$1.02M-$1.63M-$4.21M-$1.60M-$2.26M-$8.23M-$1.28M-$1.90M
Interest expense$12,959$7,360$2,400—$8,560$6,766$2,647-$43,705
Income tax————$0$0$0—
Net income-$1.03M-$1.64M-$4.21M-$1.60M-$2.27M-$8.24M-$1.28M-$1.91M
EPS (diluted)-0.27-0.43-1.12—-0.67-2.78-0.47—
Weighted avg. shares (diluted)3.82M3.81M3.75M—3.41M2.96M2.75M—
Balance sheet
Cash & equivalents$57,222$9,823$517,189$1.54M$159,403$2,466$138,641$274,380
Current assets$281,399$409,894$1.02M$1.64M$436,545$495,127$710,617$425,377
PP&E, net———————$0
Total assets$559,452$703,327$1.33M$1.64M$495,587$575,588$816,396$555,715
Current liabilities$3.61M$2.96M$2.61M$2.04M$2.58M$2.87M$3.09M$2.76M
Short-term debt——$254,454$0———$0
Total liabilities$3.85M$3.24M$2.95M$2.16M$2.58M$2.87M$3.09M$2.76M
Shareholders' equity-$3.29M-$2.54M-$1.62M-$514,898-$2.08M-$2.30M-$2.27M-$2.21M
Shares outstanding3.83M3.82M3.79M3.62M3.49M3.32M2.79M2.38M
Cash flow statement
Operating cash flow-$266,556-$476,410-$1.43M-$905,722-$1.09M-$623,654-$1.70M-$715,733
Investing cash flow$0$0$0$0$0$0$0$0
Financing cash flow$313,955-$30,956$404,985$2.29M$1.24M$487,479$1.56M-$494,530
Stock-based compensation———————-$621,159

Free plan shows the latest 8 periods; Pro shows all 61 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.